Cerebral malaria (CM) is a severe complication of Plasmodium falciparum infection, predominantly experienced by children in sub-Saharan Africa. Patients with CM are comatose and often convulse, develop retinal haemorrhages and motor abnormalities. Recent histological studies on brain tissue obtained from patients who have died from CM have identified heterogeneity in brain pathology. As a result, CM is considered to be a complex disease that may be comprised of a number of syndromes. Patients admitted to hospital with CM are treated with anti-malaria drugs; however, even in the best equipped hospitals, a large number of CM patients die within the first 24-hours following hospital admission before the anti-malarial treatment can have an effect. For this reason, it is critical that the mechanisms leading to CM are elucidated in order to develop effective adjunct therapies. Experimental cerebral malaria (ECM) caused by P. berghei ANKA (PbA) infection of susceptible mice displays many features of human CM. A key feature of this model is the pivotal role of the host immune response in pathogenesis, particularly the involvement of T cells. Evidence, predominantly from ECM studies, suggests that tumour necrosis factor (TNF) superfamily (TNFSF) members play critical roles in the immunopathology associated with CM. The first hypothesis investigated in this thesis was that key immune response pathways contribute to the development of CM and, despite the heterogeneity observed between CM patients, common pathways exist that may be targeted to prevent CM. The second hypothesis tested was that members of the TNF superfamily modulate the immune response to infection and are involved in the development of pathology observed in severe malaria (SM). In order to investigate the above hypotheses, three projects were carried out. First, we examined the great heterogeneity in brain expression profiles between ECM-susceptible CBA/CaH (CBA) and C57BL/6 (B6) mice at the peak of disease, as well as the significant differences in circulating cytokine expression and expansion of microglia in brain tissue. We found that, despite these differences, common therapeutic and preventative strategies existed to disrupt the development of ECM in the two ECM-susceptible mouse strains. Second, studies in ECM mice have identified T cells and TNFSF members, TNF and lymphotoxin (LT)-a, as critical mediators of ECM pathology. We extend these studies to examine the role of the TNFSF member LIGHT in ECM. Specific blockade of LIGHT signalling through its receptor, LTβR, in PbA-infected B6 mice abrogated the hallmark features of ECM brain pathology and improved the control of parasite growth. Importantly, specific blockade of LIGHT-LTβR signalling caused the expansion of splenic monocytes and an overall enhanced capacity to remove and process antigen during infection. Together, this study discovered a novel pathogenic role for LIGHT and LTβR in ECM and identified this TNF family receptor-ligand interaction as a potential target for therapeutic intervention in SM. Finally, we investigated the role of LTa in human SM and, more specifically, CM. We tested whether the polymorphisms within the gene encoding LTa (LTA) were associated with susceptibility to SM in Papuan Highland children and adults who had migrated from an area without malaria pressure to a region where malaria is endemic. Despite a lack of association between single nucleotide polymorphisms (SNPs) in the LTA/TNF locus and susceptibility to SM in Papuan Highland children and adults, we found a significant association between a SNP in the LTa-related gene encoding galactin-2 (LGALS2) and susceptibility to CM in children, but not adults in this study population. Interestingly, no association was found between this SNP and susceptibility to CM in Tanzanian children originating from and living in a malaria endemic region. These results suggest that there may be differences in the mechanisms leading to CM in adults and children, as well as between individuals from malaria endemic and non-endemic areas. Together, the findings outlined in this thesis are important to both the understanding of the underlying mechanisms leading to CM and to the development of improved interventions and adjunct therapies.

IgE ist das Schlüsselmolekül Typ-I allergischer Erkrankungen.. Die Produktion von IgE wird durch die Interaktion des Oberflächenmoleküls CD40 auf B-Zellen mit seinem Liganden (CD40L), dass von aktivierten T-Zellen exprimiert wird, sowie über Signale durch die Zytokine IL-4 oder IL-13 von B-Zellen produziert. Die CD40/IL-4-abhängige IgE-Produktion in vitro kann einerseits als Modell zum Verständnis der Entstehung allergischer Erkrankungen eingesetzt werden; andererseits können potenziell therapeutisch wirksame Substanzen untersucht werden. Untersuchungen zum Verständnis allergischer Erkrankungen zeigen, dass LTa nach CD40/IL-4-Stimulation von humanen B-Zellen vermehrt produziert wird und dies in autokriner Weise zu einer Steigerung der CD40/IL-4-vermittelten Proliferation und IgE-Produktion führt. Darüberhinaus wurde eine vermehrte Produktion von LTa bei allergischen Patienten nachgewiesen, so dass eine funktionelle Relevanz von LTa in der Pathogenese allergischer Erkrankungen zu vermuten ist. Die Arbeiten zu den intrazellulären Mechanismen der LTa-Induktion nach CD40/IL-4-Stimulation demonstrieren, dass sowohl der Transkriptionsfaktor NF-kB als auch verschiedene Proteinkinasen hier eine wesentliche Rolle spielen. Untersuchungen mit Hilfe des CD40/IL-4-abhängigen Systems bei humanen B-Zellen, die einen therapeutischen Einsatz zur Behandlung allergischer Erkrankungen haben könnten, zeigen, dass Retinoide aber auch Vitamin D zu einer erheblichen Hemmung der IgE-Produktion in- vitro führen. / IgE plays a key role for the development of type I related allergic diseases. Production of IgE by B cells is induced by the interaction of the surface molecule CD40 with its natural ligand (CD40L), which is expressed on activated T cells and signals which are provided by the cytokines IL-4 or IL-13. This model can be used for studies either to understand the development of allergic diseases or to investigate novel therapeutic approaches. In the context of the understanding the development of allergic diseases the present work shows that LTa is produced by B cells after CD40+IL-4 stimulation and that increased production of LTa results in enhanced CD40+IL-4 mediated B cell proliferation and IgE synthesis. Furthermore an increased production of LTa was shown in allergic patients indicating the potential role of LTa in allergic diseases. Analysis of the gene regulation of LTa after CD40 stimulation revealed an important role of the transcription factor NF-kB and showed the role of different protein kinases at the intracellular level. Studies using the CD40+IL-4 system in vitro which may have a therapeutical impact revealed that vitamin A and vitamin D are potent inhibitors of IgE production in vitro. Taken together the present work shows new mechanisms of CD40+IL-4 mediated IgE synthesis and also offers new potential therapeutical approaches of allergic diseases.